

BIBLIOGRAPHY

1. Acocella G. and Billing B.H. The effect of rifampicin SV on bile pigment in rats. *Gastroenterology*, 49, 526, 1965.
2. Acocella G., Nicolis F.B. and Lamarina A. A study on the kinetics of rifampicin in man. Vth International Congress of Chemotherapy, Vienna, p. 87 (1967).
3. Acocella G. In Proc.Symp.Rifampicin, Prague. Oct.5-9, 1970. Eds.C.J.Tousek and L.Trnka, Czechoslovak Pneumological and Phtisiological Societh of the Czeshoslovak Medical Society, Prague, 1971, p.32.
4. Acocella G. *Respiration*, Suppl.28, 1, 1971.
5. Acocella G., Lamarina A., Nicolis, G. Pagani and Segre, G. *Eur.J.Clin.Pharmacol.*, 5, 111, 1972.
6. Acocella G., Bonollo L., Mainardi M., Margarolli, P. and Nicolis F.B. Kinetics studies on rifampicin III Effect of phenobarbital on the half life of the antibiotic. *Tijdschriftroor Gastro-Enterologie*, 17,151,1974.
7. Acocella G. Clinical Pharmacokinetics of Rifampicin. *Clin.Pharmacokin.*, 3, 108, 1978.
8. Allen B.W., Ellard G.A., Mitchison D.A., Hatfield A.R.W., Kenwright S. and Levi A.J. Probenecid and serum rifampicin. *Lancet* 2, 1309, 1975.
9. Aluoch J.A., Fourth East African/British Medical Research Council. Short Course Chemotherapy Study.Bulletin of International Union against Tuberculosis, Vol.35, Bu. 4, 240, 1978.

10. Anastasatu C., Bungeleann G.H., Sibola S. Daily versus intermittent drug administration during attack phase of tuberculosis. *Chemotherapy Bulletin of International Union against Tuberculosis*, Vol.54, 1,26,1979.
11. Assandri A., Perrizzi A. and Berti M. *Jour.Antibiot.* 30, 409, 1977.
12. Barbazat G.O. The exocrine pancreas and protein-calorie malnutrition. *S.African Med.Jour.*, 41, 84, 1967.
13. Barone D., Beretta E., Tenconi L.T. Rifampicin and liver drug metabolizing system. Studies in guinea-pigs, rats and mice. *Acta Vitaminol.Enzymol.*, 26, 124, 1972.
14. Barza M. Pharmacokinetics of antibiotics. In Sabath L.D.(Ed.) *Action of Antibiotics in Patients. Proc.Int. Symp. Florence, 1981, p.11 (Huber, Berne, Stuttgart, Vienna, 1982).*
15. Bhamarapravati N. The liver in protein-calorie malnutrition. In *Protein-Calorie Malnutrition*, Olson (Ed.), p.299 (Academic Press, New York, 1975).
16. Binda G., Domenichini E., Gottardi, A., Oriandi B., Ortelli E., Pacini P. and Fowst G., *Arzneim Forsch*, 21, 1907, 1971.
17. Boekhout-Massart M.J., Bieger R., Van Brummelon P. and Lamkes H.P.J. Inhibition by rifampicin of the anti-coagulant effect of phenprocounmon. *Jour.Amer.Med. Assoc.*, 229, 1903, 1974.

18. Bolt H.M. and Remmer H. Implications of rifampicin-quinone in the irreversible binding of rifampicin to macromolecules. *Xenobiotica* 6(1),21, 1976.
19. Boman G. *Eur.Jour.Clin.Pharmacol.*, 7, 217, 1974.
20. Boman G. and Ringberger V.A. *Eur.Jour.Clin.Pharmacol.*, 7, 369, 1974.
21. Boman G., Lundgren P. and Stjernstrom G. *Eur.Clin. Jour.Pharmacol.*, 8, 293, 1975.
22. Brechbuhler S., Fluehler H., Riess W., Theobald W. The renal elimination of rifampicin as a function of the oral dose. A convenient way to assess relative bioavailability. *Arzneimittel-Forsch (Drug Res.)*, 28, 480, 1978.
23. Breimer D.D., Zilly W. and Richter E. The influence of rifampicin on drug metabolism in humans: discrepancy between hexobarbital and antipyrine. *Clin.Pharmacol.Ther.* In press, 1976. In *Pharmacokinetic Interactions with rifampicin. Clin.Pharmacokinetic.*, 2, 61, 1977. Adis Press, 1977.
24. Brock J.F. Recent advances in human nutrition. London:Churchill, 1961.
25. Brock J.F. and Hansen J.D.L. Body composition and appraisal of nutriture. In *Symposia of the Society for the Study of Human Biology. Vol.VII. Human Body Composition: Approaches and Applications.* Ed.J.Brozek, Oxford:Pergamon, Part-II, 225, 1965.

26. Buchanan N. Drug protein binding and protein-energy malnutrition. S.African Med.Jour., 52, 733, 1977.
27. Burley D.M. Rifampicin enzyme induction oestrogens and the 'pill'. In Drug Interactions. Ed.D.G.Grahme-Smith, Baltimore. University Press, 293, 1977.
28. Campbell T.C. Nutrition and drug metabolizing enzymes. Clin.Pharmacol.Ther., 22, 699, 1977.
29. Capelle P., Dhumeaux D., Mora M., Feldmann G. and Berthelot P., Gut, 13, 366, 1972.
30. Chang K.C., Bell T.D., Lauer B.A. and Chai H. Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet 1, 1132, 1978.
31. Chonjnowsky W. and Gralewicz J. Acta Pol.Pharm., 33, 325, 1976.
32. Cinti D.L., Moldeus P. and Schenkman J.B. Biochem. Pharmacol., 21, 3249, 1972.
33. Conney A.H. Pharmacological implications of microsomal enzyme induction. Pharmacol.Rev., 19, 317, 1967.
34. Craig W.A. and Kunin C.M. Significance of serum protein and tissue binding of antimicrobial agents. Ann.Rev.Med., 27, 287, 1976.
35. Craig W.A. and Welling P.G. Protein binding of antimicrobials: Clinical Pharmacokinetic and therapeutic implications. Clin.Pharmacokin., 2, 252, 1977.

36. Crosby W.H. A concept of pathogenesis on anaemia applied to disorders of the intestinal mucosa. *Amer.Jour.Digest.Dis.*, 6, 492, 1961.
37. Cruci G., Ninni A. and Jodice F. Quelques considerations sur la pharmacokinetique de la rifampicine. *Acta Tuberculosea et Pneumologica Belgia*, 60, 276, 1969.
38. Cruci G., Bergamini N., Delli Veneri F., Ninni A. and Nitti V., *Arch.Monaldi*, 25, 427, 1970.
39. DeGregorio P., LaMonica G., Massaro G. and Campo. In *Simp.Naz.Rifampicina*, Rome, Nov.20-21, Vol.1,1970, Edizioni Rassegna Medica, Sagdos-Brugherio, Milano,1971. p.144 B, 1970.
40. De Raultin de la Roy Y., Beauchant G., Brenil K. and Putte F. Diminution du taux serique de rifampicine per le phenobarbital. *Press Medicale*, 79, 350, 1971.
41. Dettli, L. The pharmacokinetics of Rimactane in patients with normal liver and kidney function. In A Symposium on Rimactane, Basle, 1968, p.28 (Ciba, Basle, 1969).
42. Dickinson J.M., Mitchison D.A. and Awaness A. Experimental evidence of the mechanisms of intermittent chemotherapy with isoniazid and rifampicin. 258th Meeting Danish Pneumology Soc. In *Int.Symp.Scanticon*, Arhus, Denmark, 1971, p.9 (Ciba-Geigy Aktiese Iskab, Copenhagen, 1972).

43. Dickinson J.M. Experimental aspects of intermittent treatment of tuberculosis. In Riska N., Hellstrom P.E. (Eds.) Symposium on Rifampicin in Tuberculosis Treatment. Helsinki, 1974, 2nd Ed., p.13 (Undermann Kirjapaino, Oy, Helsinki, 1974).
44. Doub L. The chemical structures, properties and mechanism of action of the antituberculous drugs. In Tuberculosis, p.435, Youmans G.P.(Ed.) (Saunders, Philadelphia/London/Toronto, 1979).
45. Edwards O.M., Courtenoy Evans R.J., Galley J.M., Hunter J. and Tait A.D. Changes in cortisol metabolism following rifampicin therapy. Lancet 2, 549, 1974.
46. Elue H., Karubach E., Kalaza P., Hermann, H. Preliminary results of controlled therapeutic trial administering Isoniazid-Rifampicin once weekly after or without an initial period of continuous treatment. Scand.J.Resp. Dis., Suppl.84, 153, 1973.
47. E.Poli-Sandri and D'Alessio A. Arch.Monaldi, 26, 307, 1971.
48. Epstein W.L., Shah V.P. and Riegelman S. Griseofulvin levels in stratum corneum. Study after oral administration in man. Arch.Dermat., 106, 344, 1972.
49. Ezer G. and Soothill J.F. Intracellular bactericidal effects of rifampicin in both normal and chronic granulomatous disease polymorphs. Arch.Dis.Child, 49, 463, 1974.

50. Falase A.O., Salako L.A. and Amines S.M. Lack of effect of low doses of prazosin in hypertensive Nigerians. *Curr.Ther.Res.*, 19, 603, 1976.
51. Fallon R.J., Lees A.W., Allen G.W., Smith J. and Tyrrell W.F. Probenecid and rifampicin serum levels. *Lancet* 2, 792, 1975.
52. Farr B., Mandell G.L. Rifampin. *Clin.North Amer.*, 66, 157, 1982.
53. Fox W. and Mitchison D.A. State of art:Short course chemotherapy of pulmonary tuberculosis. *Amer.Rev. Resp.Dis.* III, 325, 1975.
54. Fox W. Modern management and therapy of pulmonary tuberculosis. *Proceedings of the Royal Society of Medicine*, 70, 4, 1977.
55. Fox W. The current status of short course chemotherapy. *Bull.Int.Un.Tuberc.*, 53, 268, 1978.
56. Fox W. Whither short course chemotherapy ? *Brit.J.Dis. Chest*, 75, 331, 1981.
57. Furesz S., Scotti R., Pallanza R. and Mapelli E. *Arzneim Forsch*, 17, 534, 1967.
58. Furesz S. Chemical and biological properties of rifampicin. *Antibiot et Chemother.(Basle)*, 16, 316, 1970.
59. Furesz S. *Antibiot.Chemother.*, 16, 316, 1970.
60. Gadat M., Goursolle M., Leger J.M. and Collector S.C. *Acta Cyst.*, B-31, 1454, 1975.

61. Gomi J., Aoyagi T., Yamada Y., Mitsuno Y. & Nanba A.
Laboratory & clinical studies on rifampicin. *Shinryo* 23,
1047, 1969.
62. Gopalan C. and Srikantia S.G. Nutrition and disease.
World Review of Nutrition and Dietitics. 16,97,1973.
63. Grassi G.G., de Santis G., Giura R. Attivita dei micro-
somipolmonan sulla metabolizzazione di Farmasi antituber-
colari biornale. *Italiano Di Chemotherpia*,19,72, 1972.
64. Grassi G.G. and Grassi C. Ethanol-antibiotic inter-
actions at hepatic level. *International Jour.Clin.*
Pharmac., 11, 216, 1975.
65. Grosset J. The sterilizing value of rifampicin and
pyrazinamide in experimental short course chemotherapy.
Tubercle, 59, 287, 1978.
66. Grosset J. The efficacy of short course chemotherapy
for tuberculosis. *Bull.Pan Amer.Hlth.Org.*, 14,139,1980.
67. Grumback F., Canetti G. and Le Lirzin M. Rifampicin in
daily and intermittent treatment of experimental murine
tuberculosis with emphasis on late results. *Tubercle*,
50, 280, 1969.
68. Hakim J., Fledmann G., Boivin P., Troube H., Boucherot
J., Penaud J., Guibout P. and Kreis B. Comparative study
of hepatic bilirubin and paranitrophenol glucuronyl
transferase activities III.Effect of rifampicin alone
or associated with streptomycin and isoniazid in man.
Pathologie-Biologie, 21, 255, 1973.

69. Hansen J.D.L. and Jenkinson V. Electrolyte and nitrogen metabolism in kwashiorkor. *Lancet* 2, 911, 1956.
70. Harf R., Guillaumont M., Leclercq, M., Guise B. and Forbert Y. Simultaneous study of rifampicin and isoniazid levels in serum and phagocytic cells. In *Current Chemotherapy and Immunotherapy*, Penti P., Gialdroni-Grassi G. (Eds.). *Proc. 12th International Congress Chemother.*, Florence, 1981, Vol.II, p.986 (Amer.Soc.Microbiol., Washington, 1982).
71. Hathcock J.K. and Coon J. Nutrition and drug inter-relations, Academic Press, New York, 1978.
72. Held H., Eisert R. and Von Oldershausen H.F. Pharmacokinetik von Glymidine and Tolbutamid bei akuten and chronischen Leberschaden. *Pathologie-Biologie*, 21, 255, 1973, *Arzneimittel Forschung*, 23 : 1801, 1973.
73. Helwing H. Antibiotika-Chemotherapeutika Grundlagen-Anwendung-Gefahren Ein Leitfaden für die Praxis, 3rd Ed., P.206 (Thieme, Stuttgart, 1976).
74. Higgins E.A., Davis Jr.A.W., Fiorica V., Lampietro P.F. and Vaughan J.A. Effects of two antihistamine containing compounds upon performance at three altitudes. *Aerospace Medicine*, 19, 1167, 1968.
75. Hobby G.L. and Lenert T.F. The anti-micobacterial activity of rifampicin. *Amer.Rev.Resp.Dis.*, 97,713,1968.

76. Houston J.B. and Levy D.G. Biotransformation interaction in man. IV. Acetaminophen and ascorbic acid. *Journal of Pharmaceutical Sciences*, 65, 1219, 1976.
77. Hunter J., Maxwell J.D., Steward D.A., Carella M. and Williams R. Urinary D-glucuronic acid excretion and total liver content of cytochrome P-450 in guinea-pigs; relationship during enzyme induction and following inhibition of protein synthesis. *Biochem.Pharmacol.*, 22, 743, 1973.
78. Hussels H. *Acta Tuberc.Pneumo.Belg.*, 60, 270, 1969.
79. Jaffery G. Biochemistry, genetics and environmental factors. Introduction. *Clin.Pharmacol.Ther.*, 19, 607, 1976.
80. James R., Gillette, Donald C.Davis and Henry A.Sasame. Cytochrome P-450 and its role in lung metabolism.
81. Jezequel A.M., Orlandi F. and Tenconi L.T. Changes in smooth endoplasmic reticulum induced by rifampicin in human and guinea pig hepatocytes. *Gut*, 12, 984, 1971.
82. Johnson J.D., Hand W.L., Francis J., King-Thompson M. and Corwin R.W. Antibiotic uptake by alveolar macrophages. *J.Lab.Clin.Med.*, 95, 429, 1980.
83. Krishnaswamy K. Drug metabolism and pharmacokinetics in malnutrition. *Clin.Pharmacokin.*, 3, 216, 1978.
84. Krishnaswamy K. and Tegch P.C. Diseases of tropical environment. Chapter XXX, Drug Treatment (2nd ed.) edited by Graeme S.Abenj, 1979.
85. Kamath S.A. and K.Ananth Narayan. *Anal.Biochem.*, 48, 53, 1972.

86. Kamath S.A. and Rubin E. *Biochem.Biophys.Res.Commun.*,
49, 50, 1972.
87. Karlson A.G. and Ulrich J.A. *Appl.Microbiol.*,18,692,1969.
88. Kenny M.T. and Strates B. Metabolism and pharmacokinetics
of the antibiotic rifampin. *Drug Metabolism Reviews*,
12(1), 159, 1981.
89. Kenwright S. and Levi A.J. Sites of competition in the
selective hepatic uptake of rifampicin SV, Flavaspidic
acid, bilirubin and bromosulphthalein. *Gut*,15,220,1974.
90. Kerguris M., Lardsse C., LeNormand Y. Guillerme G.
and Bourin M. Isoniazide et rifampicine chez Le Leysin
Influence sur lactique enzymation des microsomal hepa-
tique. *J.Pharmac.(Paris)*, 13(4), 525, 1982.
91. Kofman W., Galimberti H., Marra R.Y., Niveles Sericos
Y. Urinarios de rifampicina en ninos. *Dia.Med.*,
41, 477, 1969.
92. Kraeuer B. The pharmacokinetics of Rimactane in infants.
In A Symposium on Rimactane, Basle, 1968, p.35 (Ciba,
Basle, 1969).
93. Kreek M.J., Garfield J.W., Gutjahr C.L. and Glusti L.M.
Rifampicin induced methadone withdrawal. *New Eng.Jour.*
Med., 294, 1104, 1976.
94. Kreis B., Pertet S., Birenbaum J., Guibot P., Hazeman
J.J., Orin E., Predrizet S. and Weil J. Two three month
treatment regimens for pulmonary tuberculosis. *Bulletin*
of International Union against Tuberculosis. Vol.51,
71, 1977.

95. Krisch R.E., Frith L., Black E. and Hoffenberg R.
Regulation of albumin synthesis and catabolism by
alteration of dietary protein. *Nature*, 217, 578, 1968.
96. Krishnaswamy K. and Nadamuni Naidu A. Microsomal enzymes
in malnutrition as determined by plasma half-life of
antipyrine. *Brit.Med.Jour.*, 1, 538, 1977.
97. Krishnaswamy K. Drug Metabolism and Pharmacokinetics in
Malnutrition. *Clinical Pharmacokinetics*, 3, 216, 1978.
98. Krishnaswamy K.Y., Sethuraman N., Parthasarathy R.
Intermittent short term chemotherapy of pulmonary tuber-
culosis. *Ind.Jour.Tuberc.*, Vol.24, No.1, 40, 1982.
99. Kupfer D. and Levin E. *Biochem.Biophys.Res.Comm.*,
47, 611, 1972.
100. Langman M.J.S. and Smithard D.J. Antipyrine metabolism
in iron deficiency. *Brit.Jour.Clin.Pharmacol.*, 4, 631, 1977.
101. Levine G.M. and Harber L.C. The effect of humidity on
the phototoxic response to 8-methoxy psoralen in guinea-
pigs. *Acta Dermat.Venereol.*, 49, 82, 1969.
102. Le Lirzin M. Experimental and comparative data on
currently used antituberculous drugs. In *Rifampicin and
Current Policies in Antituberculosis Chemotherapy*.
Ed.Burleg D.M., *Proceedings of International Symposium*,
Ciba Foundation, London, 1972, (Ciba Laboratories,
Horsham, 1973).
103. Lowry O.H., Rosebrough N.J., Farr A.L. and Randall R.J.
J.Biol.Chem., 193, 265, 1951.

104. Lobo M.C., Mandell G.L. The effect of antibiotics on *Escherichia coli* ingested by macrophages. *Proc.Soc. exp.Biol.(New York)*, 142, 1048, 1973.
105. Lu A.V.H., Levin W., Ryan D., West S.B., Thomas P., Kowalek J., Kuntzmann R. and Conney A.H. Induction of different types of cytochrome P-450 in liver microsomes by drugs and carcinogens, in anti-convulsant drugs and enzyme induction. p.169 (*Associated Scientific Publishers, Amsterdam*, 1976).
106. Maggi N., Pasqualucci C.R., Bollotta R. and Sensi P., *Chemotherpia*, 11, 285, 1966.
107. Mandell G.L., Vest T.K., Killing of intraleukocytic *staphylococcus aureus* by rifampicin in vitro and in vivo studies. *J.Infect.Dis.*, 125, 486, 1972.
108. Mandell G.L., **Interaction** of intraleukocytic bacteria and antibiotics. *J.Clin.Invest.*, 52, 1673, 1975.
109. Margalith P. and Pagani H., *Appl.Microbiol.*, 9, 320, 1961.
110. Mata L.J., Jimenez F., Cordon M., Rosales R., Prera E., Schneider R.F. and Vieteri F. Gastrointestinal flora of children with PCM. *Amer.Jour.Clin.Nutr.*, 25, 1118, 1972.
111. Mayoral L.G., Tripathi K., Garcia F.T. and Ghitis J. Protein malnutrition induced malabsorption versus tropical sprue. *Gastroenterology*, 53, 507, 1972.
112. Mehta S., Kalsi H.K., Jayaraman S. and Mathur V.S. Chloramphenicol metabolism in children with PCM. *Amer.Jour.Clin.Nutr.*, 28, 977, 1975.

113. Miano G., Perruzi G. La rifampicina: attivita anti-bacteria, assorbimento, diffusione ed eliminazione, nell'uomo. Att. Acad. Lincei and Roma, 13, Suppl. 1, 39, 1969.
114. Mickison D.A., Dickinson J.M. Laboratory aspects of intermittent drug therapy. Postgrad. Med. Jour., 47, 737, 1971.
115. Miller D.S. and Pryne P.R. The effect of caloric intake on net dietary protein value. Proc. Nutr. Soc., 20: Xviii, 1961.
116. Mitchell J.R. and Jollows D.J. Metabolic activation of drugs to toxic substances. Gastroenterology, 68, 392, 1975.
117. Mitchison D.A., Dickinson J.M. Bactericidal mechanisms in short course chemotherapy. Bulletin of International Union against Tuberculosis. Vol. 53, No. 4, 54, 1978.
118. Mitchison D.A. Basic mechanisms of chemotherapy. Chest, 76, Suppl., 771, 1979.
119. Mroczek W.J., Fotiu S., Davidov M.E. and Finnerty Jr. F.A. Prazosin in hypertension. A double blind evaluation with methyldopa and placebo. Curr. Ther. Res., 6, 769, 1974.
120. Nair V. and Casper R. The influence of light on daily rhythm in hepatic drug metabolizing enzymes in rat. Life Sci., 8, 1291, 1969.
121. Nakagawa H. and Sunahara S. Metabolic study and controlled clinical trials in rifampicin. Chest, 61, 526, 1972.
122. Nakagawa H. and Sunahara S. Glucuronidation and desacetylation in the metabolism of rifampicin in man. 23rd International Tuberculosis Conference, Mexico City, Sept., 1975.

123. Nitti V., Veneri F.D., Ninni A. and Meola G. Rifampicin blood serum levels and half-life during prolonged administration in tuberculous patients. *Chemotherapy*, 17, 121, 1972.
124. Njaa L.R. Weight maintenance and protein intake of the young rat. *Brit.Jour.Nutr.*, 19, 443, 1965.
125. Obel A.O.K. and Vere D.W. Antipyrine and propranolol disposition in malnutrition. *East African Med.Jour.*, 55, 20, 1978.
126. Olsen R.E. Protein-calorie malnutrition. Academic Press, New York, 1975.
127. Oppolzer W. and Prelog V. *Helv.Chem.Acta* 56,2287,1973.
128. Otani G. and Remmer H. Participation of microsomal NADPH-cytochrome C-reductase in the metabolism of rifampicin. *Naunyn-Schmiederberg's Arch.Pharmacol.*, 287 (Suppl.) R-76, 1975.
129. Otten H., Plempel M., Siegenthaler W. *Antibiotika-Fibel*, 4th ed., p.552 (Thieme/Stuttgart, 1975).
130. Pallanza R., Anoli V., Furesz S., Balzoni G. Rifampicin: a new rifamycin II: Laboratory studies in the antituberculous activity and preliminary clinical observations. *Arzneimittel-Forsch (Drug Res.)*, 17, 529, 1967.
131. Patel A.G. Intermittent rifampicin in management of pulmonary tuberculosis under programme conditions,1982.
132. Pennington J.E., Dale D.C., Reynolds H.Y. and MacLowry J.D. Gentamycin sulfate pharmacokinetics: lower levels of gentamycin in blood during fever. *Jour.Infect.Dis.*, 132, 270, 1975.

133. Pessayre D. and Mazel P. Induction and inhibition of hepatic drug metabolizing enzymes by rifampicin. *Biochem.Pharmacol.*, 25, 943, 1976.
134. Pilheu J.A., De Salvo M.C., Kock O.R. Effects of anti-tuberculosis regimen containing rifampicin and isoniazid on the liver. A light and electron microscopy study. *Amer.Rev.Resp.Dis.*, 119, Suppl.409, 1979, Abstract.
135. Pimstone B., Wittmann W., Hansen J.D.L. and Murray P. Growth hormone and kwashiorkor. *Lancet* 2, 779, 1966.
136. Piriou A., Jacqueson J.M., Warnet J.M. and Caude J.R. Enzyme induction with high doses of rifampicin in Wistar rats. *Toxicology Letter*, 17, 301, 1983.
137. Platt B.S., Heard C.R.C. and Stewart R.J.C. In *Mammalian Protein Metabolism*. Eds.Munro H.N. and Allison J.B. Academic Press, New York, Vol.2, p.445, 1964.
138. Prasad S. and Krishnaswamy K. Streptomycin pharmacokinetics in malnutrition. *Chemotherapy*, 24, 333, 1978.
139. Rajalaxmi R., Nakhasi H.L. and Ramakrishnan C.R. Effect of post-weaning deficiencies in the composition of brain lipids in rats. *Ind.Jour.Biochem.Biophy.*, 11,57, 1974.
140. Ramalingaswami V. and Nayak N.C. Liver disease in India. In *Progress in Liver Diseases*. Eds.Popper and Schaffner, Vol.III, p.222 (Grune and Stratton, New York, 1970).
141. Ramkrishnan C.V., Rajendran K., Mohun K., Fox W. and Radhakrishnan S. The diet, physical activity and accommodation of patients with quiescent pulmonary tuberculosis in a poor South Indian community. A four year follow up study. *Bulletin of the World Health Organization*, 34, 553, 1966.

142. Reubi F., Sackmann W. and Plumecke L. Jour.Urol. Nephrol., 76, 829, 1970.
143. Riess W. In Symp.Rimactane, Basle, Nov.1, 1968.
144. Rosenberg I.H. and Scrimshaw N.S. Workshop on malabsorption and malnutrition. Amer.Jour.Clin.Nutr., 25, 1046, 1972.
145. Rubin E. and Lieber C.S. Malnutrition and liver diseases - an overemphasized relationship. Amer.Jour.Clin. Med., 45, 1968.
146. Salafasky B. Dangers of drug toxicity due to over dosage in South East Asia. Jour.Trop.Med.Hyg.,79,49,1976.
147. Samson J. and Lapointe N. Chronic granulomatous disease (CGD) "in vitro" enhancement of bactericidal activity of CGD phagocytes by rifampicin. Collect Ann.Inst. Pasteur, 128C/1-2, 75, 1977.
148. Sanvordekar D.R. and Lambert H.J. Environmental modification of mammalian drug metabolism and biological response. Drug Metabolism Review, 3, 201, 1972.
149. Schndel H.E., Hansen J.D.L. and Brock J.F. The biochemical assessment of protein nutritional status.
1. Marginal hypoalbuminaemia, 2.Serum cholinesterase. South African Jour.Lab.(In Med., 8, 23, 1962).
150. Schenkman J.B. and Cinti D.L. Life Sci., 11, 247, 1972.
151. Schneider R.M. and Petermann M.L. Microsomal electron transport any cytochrome P-450. Cancer Res.,10,751,1950.

152. Schoene B., Fleischmann R.A. and Remmer H. The cytochrome P-450 content and activities of various microsomal enzymes in human liver. Proceedings of the European Society for the Study of Drug Toxicity, 13, 249, 1975.
153. Shastri R.A. and Krishnaswamy K. Undernutrition and tetracycline half-life. Clin.Chim.Acta, 66, 157, 1976.
154. Shastri R.A. and Krishnaswamy K. Metabolism of sulfadiazine in malnutrition. Brit.Jour.Clin.Pharm., 1978.
155. Simon K., Rifampicin behandlung der Tuberkulose im kindesalter. Med.Klin., 70, 1095, 1975.
156. Solberg C.O. and Hellum K.B. Protection of phagocytosed bacteria against antimicrobial agents. Scand.J.Infect. Dis., Suppl., 14, 246, 1978.
157. Strebnick H.H. and Nelson M.M. Anterior pituitary function in male rats deprived of dietary protein. Endocrinology, 70, 723, 1962.
158. Suskind. In Drug Metabolism and Pharmacokinetics in Malnutrition. Clin.Pharmacokin., 3, 216, 1978, Adis Press, 1978.
159. Tandon B.N., Iyenger K.P., Deo M.G. and Saraya A.K. A study of "sprue syndrome in adults" in Northern India. Jour.Assoc.Physicians, India, 14, 193, 1968.
160. Tech P.C. Drug dosage for South East Asian patients. Medical Progress, 4:11 (Feb., 1977).

161. Tredger J.M., Smith H.M., Powell-Jackson P.R., Davis M. and Williams R. Effect of rifampicin on the mouse hepatic mixed function oxidase system. *Biochem.Pharm.*, 30, 10, 1043, 1981.
162. Tripathy S.P. Madras study of short course chemotherapy in pulmonary tuberculosis. *Bulletin of International Union against Tuberculosis*, Vol.54, No.4, 28, 1979.
163. Varley Harold. Determination of Serum Total Proteins, Albumin and Globulin Fractions by the Biuret Method, p.553, 1980.
164. Velo G.P. and Vettori G. *Gaz.Int.Med.Chir.*, 73, 2799, 1968.
165. Verbist L., Mbete B., Van Landuyt H., Darras T.H. and Gyselar A. Intermittent therapy with rifampicin once a week in advance pulmonary tuberculosis. *Chest*, Vol.61, No.6, 555, 1972.
166. Vessel E.S. and Page J.G. Genetic control of phenobarbital induced shortening of plasma antipyrine half-lives in man. *Jour.Clin.Invest.*, 48, 2202, 1969.
167. Vessel E. Relationship between drug distribution and therapeutic effects in man. *Ann.Rev.Pharmacol.*, 14m 249, 1974.
168. Viteri and Schneider. In *Drug Metabolism and Pharmacokinetics in Malnutrition*. *Clin.Pharmacokin.*, 3, 216, 1978.
169. Vonder Hoeven, Coon M.J. and Haygen D.A. *Biochem. Biophys.Res.Comm.*, 60, 569, 1974.
170. Waterlow J.C. Adaptation to low protein intake In *Protein Calorie Malnutrition*. Ed.Olson, p.23, Academic Press, New York, 1975.

171. Wehrli W., Staehelin M. Rifamycins and other ansamycins.
In Mechanism of Action of Antimicrobial and Antitumor
Agents. Ed. Corcoran J.W., Hahn, F.E. Antibiotics,
Vol. III, p.252 (Springer/Heidelberg/New York, 1974).
172. Wharton B.A. and McChesney E.W. Chloroquine metabolism
in kwashiorkor. Jour. Trop. Paed., 16, 130, 1970.
173. Winder F.G. Mode of action of the antimycobacterial
agents and associated aspects of the molecular biology
of the mycobacteria. In Ratledge C. Stanford J. (Ed.)
The Biology of the Mycobacteria, Vol. 1, p.354
(Academic Press, London, 1982).
174. Zilly W., Breimer D.D. and Richter E. Induction of
drug metabolism in man after rifampicin treatment
measured by increased hexobarbital and tolbutamide
clearance. Eur. Jour. Clin. Pharmac., 9, 219, 1975a.
175. Zilly W., Breimer D.D. and Richter E. Pharmacokinetic
interactions with rifampicin. Clinical Pharmacokinetics,
2, 61, 1977.